Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ShangPharma goes private in management buy-out

Executive Summary

Chinese CRO ShangPharma Corp., which debuted on the NYSE less than two years ago, received a non-binding proposal from Chairman and CEO Michael Xin Hui and affiliates (who together own 54%) and TPG Capital (which has an 11% stake) to acquire all of the company’s outstanding shares for a price between $8.50-9.50 per ADS.
Deal Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Includes Contract
    • Partial Acquisition
    • Payment Includes Cash for Equity

Related Companies